Show simple item record

Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients

dc.contributor.authorDjebbari, Faouzi
dc.contributor.authorRampotas, Alexandros
dc.contributor.authorVallance, Grant
dc.contributor.authorPanitsas, Fotios
dc.contributor.authorBasker, Nanda
dc.contributor.authorSangha, Gina
dc.contributor.authorSalhan, Beena
dc.contributor.authorKarim, Farheen
dc.contributor.authorAl-Kaisi, Firas
dc.contributor.authorGudger, Amy
dc.contributor.authorNgu, Loretta
dc.contributor.authorPoynton, Matt
dc.contributor.authorLam, Ho Pui Jeff
dc.contributor.authorMorgan, Lowri
dc.contributor.authorYang, Laura
dc.contributor.authorYoung, Jennifer
dc.contributor.authorWalker, Mairi
dc.contributor.authorTsagkaraki, Ismini
dc.contributor.authorAnderson, Laura
dc.contributor.authorChauhan, Saleena Rani
dc.contributor.authorMaddams, Rebecca
dc.contributor.authorSoutar, Richard
dc.contributor.authorTriantafillou, Margarita
dc.contributor.authorPrideaux, Steve
dc.contributor.authorObeidalla, Abubaker
dc.contributor.authorEyre, Toby A
dc.contributor.authorBygrave, Ceri
dc.contributor.authorKothari, Jaimal
dc.contributor.authorBasu, Supratik
dc.contributor.authorRamasamy, Karthik
dc.date.accessioned2023-03-16T18:13:18Z
dc.date.available2023-03-16T18:13:18Z
dc.date.issued2023-01-31
dc.identifier.citationDjebbari, F., Rampotas, A., Vallance, G. et al. (2023) Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients. British Journal of Haematology. https://doi.org/10.1111/bjh.18672en
dc.identifier.issn0007-1048en
dc.identifier.pmid36720464 (pubmed)
dc.identifier.doi10.1111/bjh.18672en
dc.identifier.urihttp://hdl.handle.net/2436/625150
dc.descriptionThis is an accepted manuscript of an article published by Wiley on 31/01/2023, available online: https://doi.org/10.1111/bjh.18672 The accepted version of the publication may differ from the final published version.en
dc.formatapplication/pdfen
dc.languageeng
dc.language.isoenen
dc.publisherWileyen
dc.relation.urlhttps://onlinelibrary.wiley.com/doi/10.1111/bjh.18672en
dc.subjectfrailtyen
dc.subjectisatuximaben
dc.subjectmyelomaen
dc.subjectpomalidomideen
dc.subjectreal-worlden
dc.titleFrailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patientsen
dc.typeJournal articleen
dc.identifier.eissn1365-2141
dc.identifier.journalBritish Journal of Haematologyen
dc.date.updated2023-02-27T10:38:00Z
dc.contributor.institutionDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
pubs.place-of-publicationEngland
dc.date.accepted2023-01-17
rioxxterms.funderUniversity of Wolverhamptonen
rioxxterms.identifier.projectUOW16032024SBen
rioxxterms.versionAMen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2024-01-31en
dc.description.versionPublished version
refterms.dateFCD2023-03-16T18:11:43Z
refterms.versionFCDAM


Files in this item

Thumbnail
Name:
Djebbari_et_al_Frailty_subgrou ...
Embargo:
2024-01-31
Size:
175.3Kb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/